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Aims Observational studies have suggested a mechanistic link between the leucocyte-derived enzyme myeloperoxidase
(MPO) and vasomotor function. Here, we tested whether MPO is systemically affecting vascular tone in humans.
Methods
and results
A total of 12 135 patients were screened for leucocyte peroxidase activity. We identiﬁed 15 individuals with low
MPO expression and activity (MPO
low), who were matched with 30 participants exhibiting normal MPO protein
content and activity (control). Nicotine-dependent activation of leucocytes caused attenuation of endothelial nitric
oxide (NO) bioavailability in the control group (P , 0.01), but not in MPO
low individuals (P ¼ 0.12); here the
MPO burden of leucocytes correlated with the degree of vasomotor dysfunction (P ¼ 0.008). To directly test the
vasoactive properties of free circulating MPO, the enzyme was injected into the left atrium of anaesthetized,
open-chest pigs. Myeloperoxidase plasma levels peaked within minutes and rapidly declined thereafter, reﬂecting vas-
cular binding of MPO. Blood ﬂow in the left anterior descending artery and the internal mammary artery (IMA) as
well as myocardial perfusion decreased following MPO injection when compared with albumin-treated animals
(P , 0.001). Isolated IMA-rings from animals subjected to MPO revealed markedly diminished relaxation in response
to acetylcholine (P , 0.01) and nitroglycerine as opposed to controls (P , 0.001).
Conclusion Myeloperoxidase elicits profound effects on vascular tone of conductance and resistance vessels in vivo. These ﬁnd-
ings not only call for revisiting the biological functions of leucocytes as systemic and mobile effectors of vascular tone,
but also identify MPO as a critical systemic regulator of vasomotion in humans and thus a potential therapeutic target.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Myeloperoxidase (MPO), a haeme enzyme stored in and released
by activated polymorphonuclear neutrophils (PMN), monocytes,
and macrophages, has long been considered to be an enzyme
solely involved in host defence: in the presence of its principal sub-
strate hydrogen peroxide (H2O2), MPO generates a myriad of
reactive oxygen species with documented cytotoxic properties,
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However, over the last years, MPO has gained increasing attention
as a critical mechanistic contributor to vascular inﬂammatory
disease, in particular in atherosclerosis: Circulating MPO plasma
and serum levels not only predict adverse outcome in patients
with acute coronary syndromes and heart failure, MPO is also loca-
lized to atherosclerotic plaques
2,3 and the subendothelial matrix.
4,5
Here, MPO is capable of oxidizing and carbamylating lipoproteins
thereby facilitating its uptake by macrophages and propagating
foam cell formation.
6,7 Also, MPO revealed to activate matrix
metalloproteinases (MMPs), redox- and in particular HOCl-
sensitive matrix degrading enzyme systems, critically affecting the
stability of the plaque’s ﬁbrous cap and remodelling cardiac
tissue.
8,9
Importantly, MPO not only proved to affect the structural hom-
ogeneity of the vessel wall, but was also suggested to critically
modulate signalling cascades. One of the most intensively charac-
terized signalling pathways in the vessel wall centres around
nitric oxide (NO), which is synthesized in the endothelium and
passes the subendothelial space to reach one of its effectors, the
vascular smooth muscle cell.
10,11 Given the strategic accumulation
of MPO at the interface between endothelium and media,
5 MPO
was put forward to affect vascular tone by depleting endothelium-
derived NO.
12,13
So far ex vivo assays measuring MPO-dependent NO consump-
tion and isometric tension studies assessing NO bioavailability in
explanted aortic rings from rodents suggested that MPO might
indeed adversely affect vasorelaxation.
12 However, direct evidence
for MPO to systemically affect vascular tone in vivo has not yet been
provided.
Here, we report vasoactive effects of MPO in humans and in a
large animal model. Individuals with inherited low MPO activity
were protected from leucocyte activation-induced deterioration
of vascular function. Direct MPO administration in anaesthetized
pigs increased the tone of conductance and resistance vessels
and adversely affected myocardial blood ﬂow (MBF), thereby
strengthening the concept that MPO indeed acts as a modulator
of vascular tone in vivo.
Methods
Human studies
A total of 12 135 consecutive patients undergoing assessment of the
white blood cell count at the University Hospital Hamburg-Eppendorf
were screened for neutrophil peroxidase activity using a Technicon H1
Hematology Analyzer (Bayer). Whereas no reports exist to use this
screening method for identifying patients with high PMN-derived
peroxidase activity, previous studies established a peroxidase index
below 215 as indicative of enzyme deﬁciency
14; accordingly subjects
exhibiting a peroxidase index below 215 were considered eligible
for this study. Patients had to be above age 18, healthy, and free of
overt infections (as evidenced clinically and by a C-reactive protein
level ,5 mg/L at the day of the vascular function tests). Given the
overall low incidence of MPO deﬁciency and the fact that there is
no substantial evidence that leucocyte activation by nicotine differs
between smokers or non-smokers current smoking was not an exclu-
sion criterion. However, the subjects were advised not to smoke 12 h
prior to vascular function testing and blood sampling. The primary end-
point was the between-group difference in ﬂow-mediated dilation
(FMD) during the study. The study was approved by the local Ethics
Committee of the Board of Physicians of Hamburg and was conducted
in accordance with the Declaration of Helsinki. All enrolled and
screened subjects gave written informed consent.
All subjects were treated with a 4 mg nicotine containing gum,
which was chewed for 30 min, a manoeuver reported to activate leu-
cocytes.
15 Prior to and 2 h after nicotine application blood was drawn
and forearm FMD according to the principles set by the international
brachial artery reactivity task force
16 was assessed. Plasma was
obtained and stored immediately at 2808C. Plasma levels of MPO,
MMP-9, nitrite,
17 and nicotine were determined by ELISA and by gas
chromatography-mass spectrometry (GC-MS), respectively. Polymor-
phonuclear neutrophils were isolated from whole blood anticoagu-
lated with EDTA.
18 Myeloperoxidase protein expression in PMN was
assessed by western blotting using a polyclonal antibody to MPO (Cal-
biochem). Myeloperoxidase activity in PMN was measured by determi-
nation of oxidation of tetramethylbenzidine as described previously.
5
Details are provided in the Supplementary material online.
Nitric oxide consumption was determined ex vivo in PMN lysates
from MPO
low and control subjects using an NO electrode
(amiNO-700).
To determine endothelium-dependent and independent relaxation
isolated murine aortic rings were incubated with nicotine (10 mM),
nicotine-activated leucocytes (1 h pre-incubation of WT-derived leu-
cocytes with nicotine (10 mM), MPO (20 mg/mL), or control in combi-
nation with 10 mMH 2O2 as previously.
12
Animal studies
Experimental protocol
The experiments were performed in 16 domestic male pigs (56+6 kg)
at the Animal Laboratory, University Heart Center Hamburg, Germany.
The study wasperformed in accordancewith the ‘Positionof the Amer-
ican Heart Association on Research Animal Use’ (Circulation, April
1985) and approved by the government animal care committee and
the institutional review board for the care of animal subjects. Human
MPO (18 mg/kg, Planta, Vienna, Austria) or human serum albumin
(HSA) (18 mg/kg) was injected into the left atrium (infused volume:
3+0.4 mL/animal) in a blinded, randomized manner. For quantitative
determination of MPO plasma levels blood samples were retrieved at
baseline and 1, 5, 15, 30, 60, and 90 min after MPO or HSA application
and stored at 2808C until further analysis.
Myocardial blood ﬂow measurements as well left artery descends
(LAD) and IMA ﬂow measurement were repeated at 30, 60, and
90 min. All haemodynamic parameters were continuously monitored,
and recorded during each intervention.
Vessel preparation and organ chamber studies
Internal mammary artery (IMA) segments were dissected at the end of
the experiment and endothelium-dependent and independent relax-
ation was determined in response to increasing doses of acetylcholine
(Ach, 10
29–10
26 mol/L) and nitroglycerine (NTG) as previously.
12
Myocardial blood ﬂow measurements using ﬂuorescent
microspheres
Approximately 4 × 10
6 FMs, 15 mm in diameter (Molecular Probes,
Eugene, Oregon), were injected into the left atrium during withdrawal
of a reference blood sample via the abdominal aorta as previously
described.
19 Hearts were excised and ﬁxed in 10% formaldehyde for
6–8days.Theanteriorwalloftheleftventriclewasslicedinto20wedge-
shaped transmural tissue pieces. Tissue samples and arterial blood
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metry according to the standard method described by Glenny et al.
20
Myocardial perfusion measurement using ﬂuorescent
cardiac imaging
Myocardial perfusion was assessed using a ﬂuorescent cardiac imaging
(FCI) system (LLS GmbH, Ulm, Germany) as described previously.
19
Following intravenous application of indocyanine green (ICG;
0.01 mg/kgBW) FCI sequences were recorded for 60 s (25 frames/s).
To assess myocardial perfusion by FCI the slope of ﬂuorescent inten-
sity (SFI) derived from the time dependent ﬂuorescence signal was cal-
culated and correlated to ﬂuorescent microspheres (FM) data in the
corresponding area, as previously.
19
Biochemical analyses and immunoﬂuorescence
Myeloperoxidase plasma levels were assessed by ELISA (PrognostiX).
For detection of vascular deposition of MPO, excised IMA segments
(60 mm) from animals treated with MPO (n ¼ 4) or with HSA (n ¼ 3)
were cannulated and perfused using phosphate buffered saline to
remove residual blood. Then the segments were incubated for 15 min
with phosphate-buffered saline containing unfractionated heparin
(150 mg/mL) and the eluate was collected and analysed for MPO by
ELISA. In addition vessel-adherent MPO was detected in IMA segments
by immunoﬂuorescence using a speciﬁc antibody (Calbiochem).
Further details on the animal experiments are provided in the Sup-
plementary material online.
Statistical analysis
For the human studies we aimed to detect a minimal difference in the
primary target variable, mean change in ﬂow-mediated dilation of 2% in
absolute terms, between the two groups, with a two-sided type alpha
level of 0.05 and a power of 0.80. Based on previous trials and pilot data,
we estimated the standard deviation of the difference between the two
values for the same patient to range from 20 to 50% (in relative terms),
which gave formal sample size requirements of 40 individuals. Secondary
endpoints were the between-group differences in the levels markers of
neutrophilactivationandnitrite.Categoricaldataarepresentedasfrequen-
ciesandpercentagesandwerecomparedbyx
2testorFisher’sexacttestas
appropriate. Continuous variables were tested for normal distribution
using the Kolmogorov–Smirnov test. Normally distributed variables are
presented as mean+standard deviation; for non-normally distributed
data the median and inter-quartile range are given. To consider the
subject-level match, a variance analysis was applied including the factors:
group(MPO
loworcontrol)andanindicatorvariableforthematchedtriple.
For comparison between groups Student’s unpaired t-test was used
in case of normal distribution, in case of non-normal distribution
Mann–Whitney U test was employed. For comparison within
the groups, Student’s paired t-test or Wilcoxon test was applied.
For the assessment of the relationship, Spearman’s rank correlation
or Pearson’s product-moment correlation was employed as
appropriate.
For animal studies random group means and their standard errors at
different time points were calculated using an adjusted two-way analysis
of variance. Time trends were tested based on random coefﬁcient
models with time as regressor and group as independent factor.
Within groups, trends were tested vs. no trend (slope of zero),
between-groupstrendsweretestedonequality.Fortheanalysisofrelax-
ation studies, a general linear model for repeated measures was applied.
Results
Human studies
Within the study period of 12 months, 30 out of the 12 135 exam-
ined subjects were detected to display markedly reduced or no
detectable neutrophil peroxidase activity. Of these 30 subjects,
17 met all eligibility criteria but 2 declined to participate. Accord-
ingly, 15 subjects—who were not related to each other—with low
or no expression of the active enzyme (MPO
low) were included.
The MPO
low group was matched in a 2:1 fashion with a control
group characterized by non-reduced MPO expression and/or
activity as assessed by MPO protein content and activity in isolated
PMN (n ¼ 30; control).
As displayed in Table 1, the baseline characteristics were similar
in both groups. To exclude a heparin-induced modulation of vas-
cular function, none of the subjects was on heparin at least 12 h
prior to vascular function testing. Subjects were also advised not
to smoke 12 h prior to blood sampling and vascular function
testing.
To conﬁrm that the differences in leucocyte peroxidase activity
indeed reﬂects differences in MPO protein expression and/or
activity, PMN from all participants were isolated. Polymorphonuc-
lear neutrophils lysates from individuals in the MPO
low group
revealed signiﬁcantly reduced immunoreactivity for MPO when
compared with participants in the control group (Figure 1A).
Since the active form of MPO is processed by cleavage of precur-
sors and deﬁciency in the active enzyme does not exclude the
presence of these MPO precursors, lysates were also analysed
for MPO activity, which was reduced in the MPO
low group and
thus recapitulated the results obtained for total peroxidase activity
in whole blood (Figure 1B).
Upon nicotine exposure, plasma levels of nicotine were compar-
able between both groups (MPO
low: 6.05+7.1 ng/mL vs. control:
5.23+3.0 ng/mL; P ¼ 0.59) indicating a not signiﬁcantly different
systemic nicotine bioavailability between both groups.
Markers of leucocyte activation
In order to test whether nicotine indeed provoked leucocyte acti-
vation, plasma levels of MMP-9 and MPO, which are released upon
activation of neutrophils, were determined. The increase in plasma
levels of leucocyte-derived MMP-9 was similar in both groups fol-
lowing nicotine application (Figure 2A, mean increase MPO
low:
12.9+6.6 ng/mL, control: 31.8+14.9 ng/mL, P ¼ 0.39) reﬂecting
a comparable degree of leucocyte activation in both groups. As
opposed to MPO
low subjects, participants in the control group
exhibited a signiﬁcant rise in MPO plasma levels following adminis-
tration of nicotine (Figure 2B).
Vascular function tests
To further test whether nicotine-induced leucocyte activation
indeed translates into a decreased bioavailability of endothelium-
derived NO, vascular function tests were performed prior to
and following nicotine exposure. Whereas baseline FMD was
similar in both groups, nicotine administration signiﬁcantly deterio-
rated FMD in subjects with normal neutrophil peroxidase activity.
In contrast, nicotine did not lead to any change of FMD in MPO
low
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two groups and remained unchanged following nicotine exposure
(MPO
low: 6.3+2.4 vs. 6.6+2.8, P ¼ 0.75; control: 8.7+4.9 vs.
7.2+3.3, P ¼ 0.76; between groups: pre-treatment P ¼ 0.59,
post-treatment P ¼ 0.15). Nitroglycerine-mediated dilation
(NMD) was signiﬁcantly greater in MPO
low subjects when com-
pared with the control group at baseline and following nicotine
administration, with nicotine not signiﬁcantly altering NMD
within the groups (Figure 3B). Correlation analysis revealed a signiﬁ-
cant inverse correlation between FMD and MPO plasma levels
prior to and following nicotine application (r ¼ 20.33, P ¼ 0.03;
r ¼ 20.30, P ¼ 0.04). Also, FMD upon nicotine application was
inversely related to MPO activity in PMN (r ¼ 20.48, P ¼ 0.003,
Figure 3C). Ex vivo NO consumption by cell lysates from isolated
PMN was signiﬁcantly reduced in MPO
low subjects when compared
with controls. If PMN lysates from MPO
low subjects were fortiﬁed
with exogenous MPO NO consumption was reconstituted
(Figure 3D).
Ex vivo endothelium-dependent and independent function
testing underscored the leucocyte activating effects of nicotine
and reinforced the tenet, that nicotine-induced liberation of
MPO from leucocytes signiﬁcantly contributes to endothelial dys-
function (see Supplementary material online, Figure S1).
MPO
low subjects also displayed signiﬁcantly higher baseline
plasma levels of nitrite, a surrogate of NO availability, when com-
pared with controls (2.98+1.11 vs. 1.5+0.75 mM, P , 0.001,
Figure 3E) with baseline nitrite plasma levels being inversely corre-
lated to circulating MPO (r ¼ 20.40, P ¼ 0.034). Nicotine treat-
ment did not signiﬁcantly impact on nitrite plasma levels.
(3.41+1.05 vs. 1.8+1.23 mM, P ¼ 0.001 between groups; P ¼
0.31 and P ¼ 0.32 vs. baseline). There was no correlation
between baseline vessel diameter and nitrite.
Animal studies
In order to explore whether free MPO is capable of systemically
regulating vascular tone independent of the activation state of leu-
cocytes, MPO was given to anaesthetized open-chest pigs. The
study cohort consisted of 10 animals, which received MPO and 6
animals being challenged with HSA. One pig in the MPO group
was lost during the experiment due to sustained ventricular
arrhythmias, leaving nine pigs in the MPO group for ﬁnal
assessment.
Biochemical analysis
At baseline, MPO plasma levels were undetectable in both groups,
indicating that intrinsic, pig-derived MPO was not recognized by
the MPO-antibody used for the ELISA. Plasma levels of the admi-
nistered MPO peaked immediately after injection and rapidly
declined thereafter (Figure 4), suggesting a redistribution of the
enzyme with binding of MPO to extraplasmatic compartments. In
the control group no signiﬁcant MPO levels could be detected
(Figure 4).
...............................................................................................................................................................................
Table 1 Baseline clinical characteristics
MPO
low (n 5 15) Control (n 5 30) P-value
Age, years 56+14.7 56+15.8 0.887
Gender (male),% 40.0 40.0 0.629
BMI, kg/m
2 24.7+4.2 23.5+3.4 0.284
Hypertension,% 46.7 46.7 0.623
Hyperlipoproteinaemia,% 26.7 26.7 0.632
Diabetes mellitus,% 20.0 20.0 0.644
Current smoking,% 20.0 20.0 0.644
ASA,% 20.0 26.7 0.460
Clopidogrel,% 6.7 6.7 0.714
Beta-blockers,% 46.7 33.3 0.292
ACE-Inhibitors,% 20.0 26.7 0.460
CSE inhibitor,% 26.7 23.3 0.540
Haemoglobin, g/dL 13.0+1.1 13.6+1.4 0.226
Leucocytes, 10e
6/mL 7.48+4.65 6.55+2.25 0.375
Creatinine, mg/dL 1.06+0.44 1.04+0.64 0.914
C-reactive protein, mg/dL 0.87+2.29 1.11+2.68 0.762
Total cholesterol, mg/dL 171.4+42.0 186.7+48.1 0.302
LDL, mg/dL 86.7+27.2 102.0+34.6 0.144
HDL, mg/dL 63.7+13.9 62.3+19.1 0.811
Triglycerides, mg/dL 134.3+78.7 111.7+71.4 0.338
RRsys, mmHg 130+21 140+30 0.371
RRdia, mmHg 77+15 77+12 0.900
Heart rate, b.p.m. 68+11 69+10 0.830
BMI, body mass index; ASA, acetyl salicylic acid; ACE, angiotensin-converting enzyme, CSE, cholesterol synthase; MPO, myeloperoxidase. Mean+SD.
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mammary artery and left artery descends
In the control group, IMA and LAD ﬂow remained unchanged
throughout the entire study (P ¼ 0.563 and P ¼ 0.706), whereas
IMA and LAD ﬂow decreased signiﬁcantly in the MPO group
[mean decrease per 30 min: 30.2 (95% CI: 22.5–37.9) mL/min
and 7.5 (95% CI: 4.1–10.9) mL/min, P , 0.001, Figure 5A].
Myocardial blood ﬂow and perfusion
In order to test whether MPO also impacts on vascular tone of
resistance vessels, MBF was assessed using FM. Figure 5B depicts
MBF assessed at baseline and 30, 60, and 90 min after MPO injec-
tion in the LAD area. In the HSA group, MBF increased throughout
the experiment (P ¼ 0.026 for trend). In contrast, animals sub-
jected to MPO revealed a markedly reduced MBF during the
course of the experiment (P ¼ 0.009 for trend). The difference
between the two treatment groups was highly signiﬁcant (P ¼
0.006).
Myocardial perfusion (SFI) assessed by FCI revealed no changes
over time in the HSA-treated animals (P ¼ 0.890 for trend),
whereas SFI decreased signiﬁcantly in the MPO-treated animals
(P , 0.001 for trend, Figure 5C). Slope of ﬂuorescent intensity
was signiﬁcantly different between the two groups (P ¼ 0.002).
Haemodynamic measurements
To assess whether systemic application of MPO ﬁnally affects hae-
modynamics, systemic vascular and pulmonary vascular resistance
(PVR) was assessed (Table 2). Given that open-chest animal exper-
iments lead to signiﬁcant loss of ﬂuid the central venous pressure
(CVP) was assessed throughout the experiment. In order to
reliably assess the ﬂuid status of the animals, the heart rate was
kept at 100 b.p.m. using a pacemaker. To keep the CVP constant,
the infused volume of sodium chloride was lower in the MPO
group when compared with the HSA group infused volume of
sodium chloride (1.0+0.2 l vs. 1.8+0.3 l). Despite reduced
volume administration in the MPO group, pulmonary artery
pressure (PAP) as well as PVR increased signiﬁcantly in MPO-
treated animals (P ¼ 0.028 and P ¼ 0.003) when compared with
the HSA group (Table 2). The systemic vascular resistance (SVR)
did not change signiﬁcantly in both treatment groups (Table 2).
Of importance, all animals were normoxemic throughout the
experiments.
Figure 1 Assessment of myeloperoxidase protein expression
and enzyme activity in human neutrophils. (A) Densitometric
analysis of myeloperoxidase protein expression of all participants
(MPO
low: n ¼ 15; control n ¼ 30). (B) Quantiﬁcation of peroxi-
dase activity in isolated polymorphonuclear neutrophils from all
participants.
Figure 2 Leucocyte activation at baseline and following nic-
otine administration in humans with normal and reduced myelo-
peroxidase activity. (A) Matrix metalloproteinase-9 plasma levels
before and after stimulation with nicotine. (B) Myeloperoxidase
plasma levels before and following nicotine administration are
shown. Data are displayed for the 15 subjects with reduced mye-
loperoxidase expression and/or activity (MPO
low) subjects and
for the 30 matched controls.
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adherent myeloperoxidase
In order to explore whether alterations in vascular tone are a
reﬂection of NO oxidation by MPO, IMA-segments from HSA-
and MPO-treated animals were explanted and vessel relaxation
in response to Ach was tested: vessel segments from MPO-treated
animals revealed markedly reduced relaxation in response to Ach
(89.4+4% in rings from HSA-treated animals vs. 56.9+3% in
MPO-treated pigs, P , 0.01, Figure 6A). Exogenous addition of
the MPO substrate H2O2 prior to Ach challenge further attenu-
ated NO-dependent relaxation in vessels from MPO-treated
animals (56.9+3 and 45.4+4% after addition of H2O2, P ¼
0.021), whereas vessels from HSA-treated pigs revealed no
further impairment of vessel relaxation upon H2O2 (89.5+5%
before and 89.4+4% after addition of H2O2, P ¼ 0.381,
Figure 6A). In addition, non-endothelial-derived relaxation in
response to NTG was also attenuated in vessels rings from MPO-
treated animals (P , 0.001; Figure 6B).
In order to test, whether decreased NO bioavailability and con-
comitant attenuated relaxation in rings from animals exposed to
MPO was indeed reﬂected by association of MPO with the
vessel wall, explanted IMA segments were perfused with heparin
containing buffer. Perfusion partially recovered MPO, reﬂecting
release of vessel-adherent MPO by heparin (P ¼ 0.03 vs. HSA-
treated vessel explants; Figure 6C). Immunohistochemistry
re-conﬁrmed vascular deposition of the enzyme in explanted
IMA segments (Figure 6D).
Discussion
The principal ﬁndings of the current study are that MPO pro-
foundly affects vascular tone of resistance and conductance
vessels, which directly impacts on forearm blood ﬂow in humans
Figure 3 Vascular function in humans with low and normal
myeloperoxidase activity in response to nicotine. (A) Flow-
mediated and (B) nitroglycerine-mediated dilation before and
after nicotine stimulation. Data are displayed for all 15 subjects
with diminished myeloperoxidase expression and/or activity
(MPO
low) subjects and for the 30 matched controls. (C) Spear-
man’s correlation between ﬂow-mediated dilation following
leucocyte activation and MPO activity. Myeloperoxidase-
dependent consumption of nitric oxide. (D) Polymorphonuclear
neutrophils derived from MPO
low subjects exhibited signiﬁcantly
less nitric oxide consumption when compared with controls.
Exogenous addition of MPO (344 pmol/L) to myeloperoxidase-
deﬁcient polymorphonuclear neutrophils restored nitric oxide
consumption. (E) MPO
low subjects also displayed signiﬁcantly
higher baseline plasma levels of nitrite when compared with
controls with baseline nitrite plasma levels being inversely corre-
lated to circulating myeloperoxidase (r ¼ 20.40, P ¼ 0.034).
Nicotine treatment did not signiﬁcantly impact on nitrite
plasma levels.
T.K. Rudolph et al. 1630and similarly affected epicardial, microvascular, and extramyocar-
dial blood ﬂow in anaesthetized pigs. Assessment of
NO-dependent and independent relaxation in humans and ex
vivo testing of NO-dependent vasorelaxation in vessels from the
treated animals reinforced the tenet that MPO-driven oxidation
of endothelium-derived NO in addition is one pivotal underlying
mechanism for the effect of MPO on vascular tone.
Although numerous studies have advocated for MPO-driven
consumption of endothelial NO, no study to date has directly
assessed the haemodynamic consequences of systemic MPO
release or administration under in vivo conditions. Whereas inves-
tigations in MPO
–/– mice assessed vascular function and endo-
thelial NO bioavailability in explanted rings of conductance
vessels following LPS challenge,
12 studies in patients with vascular
inﬂammatory disease only provided an association between MPO
and vascular dysfunction.
3,21,22
The current study now advances the concept of MPO-driven
changes in vasomotion and reveals that liberation of MPO from
leucocytes as well as administration of free MPO sufﬁces to criti-
cally inﬂuence vascular reactivity: Following nicotine exposure, a
tool to activate PMN and liberate MPO, humans with normal
MPO expression/activity displayed signiﬁcantly impaired FMD,
whereas subjects with low MPO expression/activity were pro-
tected against the nicotine-induced deterioration of FMD. This
tenet was reinforced by the observation that NO consumption
was signiﬁcantly reduced in PMN isolated from subjects with low
MPO expression/activity. The correlation between MPO and
nitrite plasma levels on the one hand and MPO levels and endo-
thelial function on the other hand further afﬁrms that MPO
indeed impacts on vascular reactivity. Interestingly, individuals
with low MPO expression/activity not only displayed improved
NO-dependent vasorelaxation, baseline assessment of
NO-independent relaxation was also augmented in the MPO
low
group. This suggests that MPO under chronic conditions, e.g. by
increased matrix turnover, post-translational oxidation of matrix
proteins or oxidation of lipoproteins, also affects the structural
integrity of the vessel wall.
Of note, the experiments performed in pigs revisited the
adverse effects of MPO on vascular function and revealed attenu-
ated vasodilation in conductance (IMA and LAD) and resistance
vessels (myocardial microvasculature). Importantly, the MPO
plasma concentrations needed to elicit these effects on vascular
tone in humans and in the animals did not exceed plasma levels
Figure 5 Effect of myeloperoxidase on blood ﬂow of conduc-
tance vessels and myocardial blood ﬂow in anaesthetized pigs. (A)
Mean internal mammary artery and left artery descends ﬂow in
the myeloperoxidase group decreased signiﬁcantly during the
course of the experiment (P , 0.001) and when compared
with human serum albumin-treated animals (P , 0.001). (B) Myo-
cardial blood ﬂow and perfusion as measured by ﬂuorescent
microspheres and ﬂuorescent imaging in myeloperoxidase and
human serum albumin-treated animals. Mean blood ﬂow
decreased signiﬁcantly in the myeloperoxidase group (P for
trend 0.009) as opposed to human serum albumin-treated
animals (P for trend 0.026). The difference between the groups
was also statistically signiﬁcant (P ¼ 0.006). (C) In accordance,
myocardial perfusion (slope of ﬂuorescent intensity) decreased
in myeloperoxidase-treated animals (P for trend ,0.001) and
remained unchanged in human serum albumin-treated animals
(P for trend 0.890). Slope of ﬂuorescent intensity was signiﬁcantly
different between the groups (P ¼ 0.002).
Figure 4 Myeloperoxidase plasma levels following injection of
human myeloperoxidase vs. human serum albumin in an open-
chest pig model. Injection of human myeloperoxidase resulted
in a rapid increase in MPO levels in pig plasma (n ¼ 9, as assessed
by ELISA), and decreased thereafter when compared with HSA-
treated (n ¼ 6) animals (*P , 0.01 vs. baseline and
#P , 0.01 vs.
1 min).
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Table 2 Haemodynamic parameters in anaesthetized pigs
Parameter Treatment Baseline 30 min 60 min 90 min P (trend) P (trend MPO
vs. trend HSA)
CO (l/min) MPO 5.74+1.51 5.60+1.03 5.47+0.94 5.19+1.05 0.0298 P ¼ 0.129
HSA 5.19+1.05 6.10+1.72 5.55+1.32 5.62+1.34 0.116
MAP (mmHg) MPO 79.9+15.9 80.4+20.5 77.4+19.2 72.3+13.5 0.012 P ¼ 0.028
HSA 72.3+13.5 72.0+6.6 72.7+10.2 76.3+6.7 0.346
PAP mean (mmHg) MPO 31.3+11.5 36.2+15.5 37.6+12.8 40.5+15.6 0.028 P ¼ 0.078
HSA 29.3+15.6 29.4+14.0 29.2+10.5 28.2+7.6 0.830
LAP mean (mmHg) MPO 8.4+2.4 9.0+3.6 8.8+3.6 8.0+2.3 0.615 P ¼ 0.669
HSA 8.0+2.3 8.5+2.9 9.3+3.4 9.2+4.1 0.467
CVP (mmHg) MPO 5.9+2.0 6.0+2.2 6.2+1.64 6.2+1.6 0.440 P ¼ 0.047
HSA 6.2+1.6 7.2+2.6 8.2+3.2 8.3+3.3 0.019
SVR (Picco) (dynes*s*cm
25) MPO 1088+425 1106+381 1099+345 1014+334 0.492 P ¼ 0.455
HSA 1014+334 934+413 964+295 1056+350 0.306
SVR (calculated) (dynes*s*cm
25) MPO 1142+536 1099+345 1077+341 1083+423 0.492 P ¼ 0.535
HSA 1083+423 933+392 979+335 1026+349 0.384
PVR (dynes*s*cm
25) MPO 279+127 366+136 397+142 464+229 0.001 P ¼ 0.003
HSA 222+145 239+148 248+173 249+118 0.54
CO, cardiac output; MAP, mean blood pressure; PAP, pulmonary artery pressure; LAP, left atrial pressure; CVP, central venous pressure; SVR, systemic vascular resistance and
PVR, pulmonary vascular resistance. Mean+SD.
Figure 6 Nitric oxide-dependent relaxation of explanted pig vessel segments and vascular myeloperoxidase deposition. (A) Relaxation of
explanted segments of the internal mammary artery in response to acetylcholine. There was a signiﬁcant attenuation of acetylcholine-
dependent relaxation in vessel segments from animals treated with myeloperoxidase (56.9+3% in myeloperoxidase-treated pigs vs.
89.4+4% in rings from human serum albumin-treated animals, P , 0.01). Addition of H2O2 further decreased acetylcholine-dependent vasor-
elaxation in rings explanted from myeloperoxidase-treated animals (45.4+4%, *P ¼ 0.021), whereas vessel segments from human serum
albumin-treated animals showed no H2O2-dependent impairment of vessel relaxation (89.5+5%). (B) Nitroglycerine-induced relaxation
was signiﬁcantly reduced in explanted segments of the internal mammary artery derived from myeloperoxidase-treated animals (P , 0.001).
(C) Heparin-dependent liberation of myeloperoxidase after ex vivo perfusion of explanted pig internal mammary artery. Vessels from
myeloperoxidase-treated animals revealed increased levels of myeloperoxidase in the eluate when compared with human serum albumin-
treated pigs. (D) Immunoﬂuorescent imaging displayed vascular myeloperoxidase deposition in explanted internal mammary artery segments
of myeloperoxidase-treated pigs when compared with human serum albumin-treated animals (red, PECAM; green, MPO; blue, DAPI; magniﬁ-
cation ×200).
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disease, heart failure, or sepsis
23–25 and thus have to be con-
sidered pathophysiologically relevant. On the other hand, the
highly dynamic change in MPO plasma levels upon exogenous
MPO administration elucidates the fate of MPO in the vasculature:
myeloperoxidase plasma levels peaked within minutes after injec-
tion and rapidly declined thereafter. The fact that MPO leaves
the circulatory compartment not only is an important observation
reﬂecting the avidity of this enzyme to bind to the vessel wall, but it
also demonstrates that assessment of circulating MPO levels in
plasma or serum poorly reﬂects the non-PMN associated, ‘free’
fraction of this enzyme. In other words, circulating MPO levels
as determined in patients with acute coronary syndromes, heart
failure, or acute septic disease might signiﬁcantly underestimate
the extent of vascular-immobilized MPO. Heparins have been
shown to compete with extracellular matrix proteins for binding
of MPO with the extent of MPO liberation being an indicator of
vascular NO bioavailability.
22 In agreement with these ﬁndings,
MPO was not only localized to the vessel wall by means of immu-
nohistochemistry, vessel-immobilized MPO could also been
retrieved upon heparinization. Importantly, MPO containing
vessel rings were indicative of substantially attenuated vasorelaxa-
tion: Organ chamber isometric tension studies revealed signiﬁ-
cantly attenuated acetylcholine-dependent and thus NO-induced
vasorelaxation in vessel segments from MPO-treated animals.
These studies also demonstrate that MPO positive vessel rings
even in the absence of exogenously added H2O2—the substrate
of MPO—were indicative of reduced vasorelaxation. This implies
that endogenous sources of H2O2 in the vessel wall provide sufﬁ-
cient substrate for MPO in vivo, which further supports the notion
that MPO is capable of affecting vascular NO bioavailability remote
of its degranulating host cell. The fact that NTG-induced relaxation
was also attenuated in vessels from MPO-treated animals revisits
the observations made in humans, and suggests that MPO also
impacts on the structural integrity of the vessel wall.
Interestingly, the vasoactive properties of MPO were not only
restricted to conductance vessels like the brachial artery in
humans and the internal mammary and the left coronary artery
in pigs, MPO also affected resistance vessels: Myocardial blood
ﬂow and perfusion as assessed by FM and FCI was signiﬁcantly
diminished in the animal model. Myeloperoxidase-dependent
modulation of vascular tone was not restricted to the myocardial
circulation but rather holds true for the pulmonary vascular
system also: In pigs exposed to MPO, PAP and PVR increased.
Given that MPO-treated animals were volume-restricted to keep
the CVP equal between groups, the effect of MPO on PAP and
resistance may even be underestimated. The fact that mean PAP
and PVR increased upon MPO administration underscores the
haemodynamic signiﬁcance of the observed MPO effects since pul-
monary vasomotion is vastly independent of circulatory
reﬂexes.
26–28 Taken together, the MPO-induced increase in PVR
on the one hand and the decrease in myocardial perfusion on
the other hand accounted for the decrease in cardiac output,
which drove the decrease in blood pressure in the MPO group.
Lower LDL levels as confounders for attenuated
nicotine-induced endothelial dysfunction in MPO-deﬁcient individ-
uals were excluded by multivariate regression analysis. Certainly,
the current study bears several limitations: (i) Using the Technicon
H1 Hematology Analyzer is not an established tool to assess MPO
deﬁciency, however it is a valid screening method before low MPO
expression/activity was validated in every single subject by means
of western blotting and activity assays. (ii) Since nicotine has vaso-
active properties, it cannot be excluded that nicotine exposure per
se altered vascular function—even if we did not observe signiﬁcant
effects of nicotine on vascular relaxation in explanted murine
aorta. (iii) Furthermore, the current data cannot exclude that
MPO elicits effects on endothelial NO bioavailability apart from
NO oxidation; e.g. MPO-dependent inactivation of endothelial
NO synthase or HOCl-mediated NO consumption, respect-
ively.
29,30 Also, MPO suggests to modulate the structural integrity
of the vessel wall, in light of the differences in
endothelial-independent vasorelaxation between MPO competent
individuals and those with low expression/activity of the enzyme.
However, given the profound differences in NO-dependent
vasomotor function between the two groups of individuals, the sig-
niﬁcant correlation between MPO activity and ﬂow-mediated
dilation following leucocyte activation and the systemic effects of
MPO administration on different vascular territories in the
animals investigated the current study provides compelling evi-
dence for MPO acting as a leucocyte-derived mediator affecting
vascular NO bioavailability in vivo. This effect of leucocytes on vas-
cular function may be physiological under states of acute infection
and sepsis, in which the secreted MPO provides a sink for the
excess synthesis of NO provided but may be detrimental under
conditions of chronic vascular disease such as atherosclerosis, in
which diffuse MPO sequestration into the vessel lumen may lead
to oxidation of endothelium-derived NO thereby pathologically
increasing vascular tone. Thus the current studies reinforces obser-
vational studies in humans with MPO deﬁciency indeed being
characterized by a reduced occurrence of cardiovascular
disease,
31 whereas increased levels of MPO were indicative of car-
diovascular disease in asymptomatic individuals.
32,33
Taken together, the current results not only call for appreciation
of alternative, vasoactive properties of leucocytes, but—with
respect to MPO—may point towards a novel, clinically applicable
target for modulating vascular NO bioavailability under inﬂamma-
tory conditions.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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